CASTLE BIOSCIENCES, INC. (CSTL) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $711.12M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-256.00K; Retained Earnings (Accumulated Deficit)USD $-240.87M; Stockholders' Equity Attributable to ParentUSD $470.03M.
- 2026-03-31: Additional Paid in CapitalUSD $700.25M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-63.00K; Retained Earnings (Accumulated Deficit)USD $-238.81M; Stockholders' Equity Attributable to ParentUSD $461.42M.
- 2025-12-31: Additional Paid in CapitalUSD $694.86M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $267.00K; Retained Earnings (Accumulated Deficit)USD $-224.28M; Stockholders' Equity Attributable to ParentUSD $470.87M.
- 2025-09-30: Additional Paid in CapitalUSD $688.73M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $240.00K; Retained Earnings (Accumulated Deficit)USD $-221.95M; Stockholders' Equity Attributable to ParentUSD $467.05M.
CASTLE BIOSCIENCES, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Outstanding USD | Common Stock, Value, Outstanding USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $711.12M | $-256.00K | $-240.87M | $470.03M | $0.00 | $31.00K | (m) | 3 month · $11.59M | (m) | (m) |
| 2026-03-31 | $700.25M | $-63.00K | $-238.81M | $461.42M | $0.00 | $30.00K | (m) | 3 month · $9.78M | (m) | (m) |
| 2025-12-31 | $694.86M | $267.00K | $-224.28M | $470.87M | $0.00 | $30.00K | (m) | 12 month · $45.89M | (m) | (m) |
| 2025-09-30 | $688.73M | $240.00K | $-221.95M | $467.05M | $0.00 | $29.00K | (m) | 3 month · $12.10M | (m) | (m) |
| 2025-06-30 | $676.76M | $39.00K | $-221.45M | $455.38M | $0.00 | $29.00K | 3 month · $11.21M | 3 month · $11.21M | (m) | (m) |
| 2025-03-31 | $666.12M | $131.00K | $-225.97M | $440.31M | $0.00 | $29.00K | 3 month · $11.18M | 3 month · $11.18M | (m) | (m) |
| 2024-12-31 | $655.70M | $230.00K | $-200.13M | $455.83M | $0.00 | $28.00K | 12 month · $50.32M | 12 month · $50.32M | (m) | (m) |
| 2024-09-30 | $650.27M | $473.00K | $-209.72M | $441.06M | $0.00 | $28.00K | 3 month · $13.03M | 3 month · $13.03M | (m) | (m) |
| 2024-06-30 | $636.02M | $-172.00K | $-211.99M | $423.89M | $0.00 | $28.00K | 3 month · $13.18M | 3 month · $13.18M | (m) | (m) |
| 2024-03-31 | $623.45M | $-111.00K | $-220.91M | $402.46M | $0.00 | $28.00K | 3 month · $12.68M | 3 month · $12.68M | (m) | (m) |
| 2023-12-31 | $609.48M | $136.00K | $-218.37M | $391.27M | $0.00 | $27.00K | 12 month · $51.22M | 12 month · $51.22M | (m) | (m) |
| 2023-09-30 | $601.62M | $-71.00K | $-215.79M | $385.78M | $0.00 | $27.00K | 3 month · $13.04M | (m) | (m) | (m) |
| 2023-06-30 | $587.77M | $-144.00K | $-208.89M | $378.77M | $0.00 | $27.00K | 3 month · $12.85M | (m) | (m) | (m) |
| 2023-03-31 | $575.37M | $-136.00K | $-190.11M | $385.15M | $0.00 | $27.00K | 3 month · $13.53M | (m) | (m) | (m) |
| 2022-12-31 | $560.41M | $-381.00K | $-160.91M | $399.15M | $0.00 | $27.00K | 12 month · $36.32M | (m) | (m) | (m) |
| 2022-09-30 | $551.88M | $-189.00K | $-140.29M | $411.43M | $0.00 | $26.00K | 3 month · $9.20M | (m) | (m) | (m) |
| 2022-06-30 | $541.67M | (m) | $-120.04M | $421.66M | $0.00 | $26.00K | 3 month · $8.78M | (m) | (m) | (m) |
| 2022-03-31 | $515.70M | (m) | $-118.39M | $397.34M | $0.00 | $25.00K | 3 month · $8.42M | (m) | (m) | (m) |
| 2021-12-31 | $505.48M | $0.00 | $-93.77M | $411.74M | $0.00 | $25.00K | 12 month · $21.74M | (m) | (m) | (m) |
| 2021-09-30 | $499.05M | (m) | $-87.36M | $411.73M | $0.00 | $25.00K | 3 month · $5.21M | (m) | (m) | (m) |
| 2021-06-30 | $491.46M | (m) | $-75.57M | $415.94M | $0.00 | $25.00K | 3 month · $4.77M | (m) | (m) | (m) |
| 2021-03-31 | $485.34M | (m) | $-66.78M | $418.61M | $0.00 | $25.00K | 3 month · $4.91M | (m) | (m) | (m) |
| 2020-12-31 | $478.16M | (m) | $-62.50M | $415.69M | $0.00 | $25.00K | 12 month · $8.31M | (m) | (m) | (m) |
| 2020-09-30 | $224.15M | (m) | $-57.61M | $166.56M | $0.00 | $20.00K | 3 month · $2.12M 9 month · $5.35M | (m) | (m) | (m) |
| 2020-06-30 | $210.62M | (m) | $-53.02M | $157.62M | $0.00 | $19.00K | 3 month · $1.65M 6 month · $3.23M | (m) | (m) | (m) |
| 2020-03-31 | $139.56M | (m) | $-51.64M | $87.93M | $0.00 | $17.00K | 3 month · $1.58M | (m) | (m) | (m) |
| 2019-12-31 | $137.31M | (m) | $-52.21M | $85.11M | $0.00 | $17.00K | 12 month · $1.25M | (m) | 12 month · $8.38M | 12 month · $15.27M |
| 2019-09-30 | $136.59M | (m) | $-54.27M | $82.34M | $0.00 | $17.07K | 3 month · $229.00K 9 month · $536.00K | (m) | 9 month · $8.38M | 3 month · $15.27M 9 month · $15.27M |
| 2019-06-30 | $9.91M | (m) | $-60.12M | $-50.20M | (m) | $2.19K | 3 month · $139.00K 6 month · $307.00K | (m) | 6 month · $8.38M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $-49.43M | (m) | (m) | 3 month · $168.00K | (m) | 3 month · $8.38M | (m) |
| 2018-12-31 | $921.00K | (m) | $-57.49M | $-56.57M | $0.00 | $2.00K | 12 month · $294.00K | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | $-60.45M | (m) | (m) | 3 month · $74.39K 9 month · $220.73K | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | $-57.05M | (m) | (m) | 3 month · $84.63K 6 month · $146.34K | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | $-53.93M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $-50.31M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |